Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Capricor Therapeutics (CAPR) EPS (Basic) (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of EPS (Basic) data on record, last reported at -$0.54 in Q3 2025.

  • For Q3 2025, EPS (Basic) fell 42.11% year-over-year to -$0.54; the TTM value through Sep 2025 reached -$1.75, down 71.57%, while the annual FY2024 figure was -$1.15, 38.55% down from the prior year.
  • EPS (Basic) reached -$0.54 in Q3 2025 per CAPR's latest filing, up from -$0.57 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.02 in Q4 2023 and bottomed at -$0.57 in Q2 2025.
  • Average EPS (Basic) over 5 years is -$0.3, with a median of -$0.29 recorded in 2022.
  • Peak YoY movement for EPS (Basic): soared 106.45% in 2023, then plummeted 650.0% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$0.26 in 2021, then fell by 19.23% to -$0.31 in 2022, then skyrocketed by 106.45% to $0.02 in 2023, then tumbled by 650.0% to -$0.11 in 2024, then tumbled by 390.91% to -$0.54 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.54 in Q3 2025, -$0.57 in Q2 2025, and -$0.53 in Q1 2025.